{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T13:12:29Z","timestamp":1774617149070,"version":"3.50.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1097\/iae.0b013e318297f842","type":"journal-article","created":{"date-parts":[[2013,7,11]],"date-time":"2013-07-11T12:25:24Z","timestamp":1373545524000},"page":"342-351","source":"Crossref","is-referenced-by-count":92,"title":["EFFICACY AND SAFETY OF TWO OR MORE DEXAMETHASONE INTRAVITREAL IMPLANT INJECTIONS FOR TREATMENT OF MACULAR EDEMA RELATED TO RETINAL VEIN OCCLUSION (SHASTA STUDY)"],"prefix":"10.1097","volume":"34","author":[{"given":"Antonio","family":"Capone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Dodwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard F.","family":"Dreyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kean T.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel B.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"Walt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanita C.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-16-20210130","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1111\/j.1538-7836.2010.03909.x","article-title":"Retinal vein thrombosis: pathogenesis and management.","volume":"8","author":"Rehak","year":"2010","journal-title":"J Thromb Haemost"},{"key":"R2-16-20210130","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/02713680701851902","article-title":"Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities.","volume":"33","author":"Rehak","year":"2008","journal-title":"Curr Eye Res"},{"key":"R3-16-20210130","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ophtha.2006.11.011","article-title":"Interventions for central retinal vein occlusion: an evidence-based systematic review.","volume":"114","author":"Mohamed","year":"2007","journal-title":"Ophthalmology"},{"key":"R4-16-20210130","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.5301\/ejo.5000162","article-title":". Visual acuity outcome and predictive factors after bevacizumab for central retinal vein occlusion.","volume":"22","author":"Daien","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"R5-16-20210130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000327391","article-title":". Management of retinal vein occlusionconsensus document.","volume":"226","author":"Coscas","year":"2011","journal-title":"Ophthalmologica"},{"key":"R6-16-20210130","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0002-9394(84)90316-7","article-title":"Argon laser photocoagulation for macular edema in branch vein occlusion.","volume":"98","year":"1984","journal-title":"Am J Ophthalmol"},{"key":"R7-16-20210130","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0161-6420(95)30849-4","article-title":"Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report.","volume":"102","author":"Central Vein Occlusion Study Group","year":"1995","journal-title":"Ophthalmology"},{"key":"R8-16-20210130","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/ICU.0b013e3283524148","article-title":"Best practices for treatment of retinal vein occlusion.","volume":"23","author":"Hahn","year":"2012","journal-title":"Curr Opin Ophthalmol"},{"key":"R9-16-20210130","first-page":"1648","article-title":"; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-1114.","volume":"127","author":"Ip","year":"2009","journal-title":"Erratum in: Arch Ophthalmol"},{"key":"R10-16-20210130","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"; for the OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"R11-16-20210130","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"; for the Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.","volume":"118","author":"Haller","year":"2011","journal-title":"Ophthalmology"},{"key":"R12-16-20210130","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":". Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"key":"R13-16-20210130","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","article-title":". Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"issue":"suppl 1","key":"R14-16-20210130","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000337157","article-title":"Anti-vascular endothelial growth factor treatment for retinal vein occlusions.","volume":"227","author":"Campochiaro","year":"2012","journal-title":"Ophthalmologica"},{"key":"R15-16-20210130","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1167\/iovs.10-5285","article-title":". Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant.","volume":"52","author":"Chang-Lin","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R16-16-20210130","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/archopht.125.3.309","article-title":"; Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema.","volume":"125","author":"Kuppermann","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R17-16-20210130","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/IAE.0b013e318188c814","article-title":". Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema.","volume":"29","author":"Haller","year":"2009","journal-title":"Retina"},{"key":"R18-16-20210130","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","article-title":"Novel method for analyzing Snellen visual acuity measurements.","volume":"30","author":"Gregori","year":"2010","journal-title":"Retina"},{"key":"R19-16-20210130","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/IAE.0b013e3181dcfaf3","article-title":". Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema.","volume":"30","author":"Blumenkranz","year":"2010","journal-title":"Retina"},{"key":"R20-16-20210130","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000343643","article-title":"Repeated treatment for macular edema in vein occlusion by intravitreal implant of dexamethasone.","volume":"3","author":"Matonti","year":"2012","journal-title":"Case Rep Ophthalmol"},{"key":"R21-16-20210130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000342160","article-title":". Repeated intravitreal dexamethasone implant (Ozurdex) for retinal vein occlusion.","volume":"229","author":"Querques","year":"2013","journal-title":"Ophthalmologica"},{"key":"R22-16-20210130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00417-010-1470-2","article-title":"; Retinal Vein Occlusion Study Group. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion.","volume":"249","author":"Jaissle","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R23-16-20210130","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.ophtha.2011.12.028","article-title":". Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant.","volume":"119","author":"Yeh","year":"2012","journal-title":"Ophthalmology"},{"key":"R24-16-20210130","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/bjo.68.3.196","article-title":"Retinal branch vein occlusion: a study of argon laser photocoagulation in the treatment of macular oedema.","volume":"68","author":"Shilling","year":"1984","journal-title":"Br J Ophthalmol"},{"key":"R25-16-20210130","first-page":"1289","article-title":". Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion.","volume":"32","author":"Singer","year":"2012","journal-title":"Retina"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0b013e318297f842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:46:26Z","timestamp":1620953186000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201402000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e318297f842","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}